We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Category:Bio Products > Sera and Vaccines > Vaccine Product Name:Quadrivalent Influenza Vaccine in 2022 CAS No.:1234 Standard:ChP, In-house Standards Price(USD):8 Company:Hualan Biological Vaccine Inc.
Main Sales Markets: North America,Eastern Europe,Asia,Middle East,Africa
Monthly Production Capacity: 30000000
Contract Manufacturing: CRO,CMO
Packaging Information: vials or syringe
Delivery Lead Time: 1 month
Sample Provided: yes
Payment Terms: T/T
[Vaccination Subjects]
The vaccine is approved for use in people aged 3 and above, especially in vulnerable people and high risk population for influenza complications, such as children, the elderly, the weak and people in influenza epidemic areas.
[Active ingredients] Hemagglutinin of prevalent strains of influenza virus in 2022-2023 northern and southern hemisphere influenza season.
an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
an A/Darwin/9/2021 (H3N2)-like virus;
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus
[Excipients] Na2HPO4, NaH2PO4, NaCl. [Specifications] 0.5ml per vial (syringe), 0.5ml human dose for each use, contains 15µg HA of each type of influenza strains.
Three years of qualification
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
